May 23 – British drugmaker GlaxoSmithKline said on Thursday it will change incentives for sales representatives in some countries as it looks to retain talent. The changes mark a cautious return by GSK to performance based bonuses for sales reps after stopping them for years in response to a bribery scandal. The company said the changes reflected the shift in GSK’s portfolio towards innovative specialty care products, including oncology. GSK said it would make changes to its incentive programme for pharmaceutical and vaccines sales representatives, to be applied initially in the United States, UK and Canada from July 2019.
Click here to read the full article